Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers

The National Academy of Clinical Biochemistry

Laboratory Medicine Practice Guidelines

Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers

Publication Date: 2010

We present here to clinical chemists, clinicians and other practitioners of laboratory and clinical medicine the latest update of the national Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for the use of tumor markers in liver, bladder, cervical, lung and gastric cancers. These guidelines are intended to encourage more appropriate use of tumor marker tests by primary care physicians, hospital physicians and surgeons, specialist oncologists, and other health professionals.

Guidelines Committee:

  • Catharine M. Sturgeon, Department of Clinical Biochemistry, Royal Infirmary of Edinburgh, Edinburgh, UK
  • Michael J. Duffy, Department of Pathology and Laboratory Medicine, St Vincent’s University Hospital and UCD School of Medicine and Medical Science, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland
  • Barry R. Hoffman, Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, and Department of Laboratory Medicine and Pathobiology, University of Toronto, Ontario, Canada
  • Rolf Lamerz, Department of Medicine, Klinikum of the University Munich, Grosshadern, Germany
  • Herbert A. Fritsche, Department of Laboratory Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX
  • Katja Gaarenstroom, Department of Gynecology, Leiden University Medical Center, Leiden, the Netherlands
  • Johannes M.G Bonfrer, Department of Clinical Chemistry, Netherlands Cancer Institute, Amsterdam, the Netherlands
  • Thorsten Ecke, Department of Urology, Helios Hospital, Bad Saarow, Germany
  •  H. Barton Grossman, Department of Urology, The University of Texas M. D. Anderson Cancer Center, Houston, TX
  • Peter Hayes, Scottish Liver Transplant Unit, Department of Medicine, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom
  • Ralf-Thorsten Hoffmann, Department of Clinical Radiology, LMU-Klinikum-Grosshadern, University of Munich, Germany
  • Seth P. Lerner, Department of Urology, Baylor College of Medicine, Houston, TX
  • Florian Lohe, Department of Surgery, LMU-Klinikum-Grosshadern, University of Munich, Germany
  • Johanna Louhimo, Department of Clinical Chemistry, Helsinki University Central Hospital, Finland
  • Ihor Sawczuk, Department of Urology, Hackensack University Medical Center, Hackensack,NJ
  • Kazuhisa Taketa, Clinical Trial Center, Brain Attack Center, Oota Memorial Hospital, Fukuyama, Japan
  • Eleftherios P. Diamandis, Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, and Department of Laboratory Medicine and Pathobiology, University of Toronto, Ontario, Canada

This LMPG was developed by an independent committee of the NACB. Subsequent publication of these guidelines has been supported by the Academy.